BioSpace News Archive

Bionomics Limited has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on 8 March 2021 and concurrent placement that was announced on 17 March 2021 which collectively raised approximately A$22.9 million.

Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021.

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, will present preclinical findings supporting the company’s lead product programs, SRF388 (targeting IL-27) and SRF617 (targeting CD39). These data will be presented as part of the American Association for Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually April 10-15

Evotec SE announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials.

As ventures keep on advancing toward working in a totally computerized, the medical device producers and clients are finding that the move to digital conveys a ton a number of problems.

Electronic medical record systems, sometimes used synonymously with electronic health records systems, have gained widespread traction in medical practices across the globe.

Pyrogens are substances that lead to causing fever after administration of an injection. Rise in the body temperature and body ache are some of the prominent reactions that are caused because of injection of these harmful pyrogens in the human body.

Microbial identification has become an important aspect of the overall healthcare domain. With the growing prevalence of infectious diseases, increasing frequency of global pandemic, and rising food safety concerns the need for rapid and reliable microbial identification has become highly important.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced the abstract results of the final 5 year immune response data of the Phase IIb clinical trial at the 2021 AACR Annual Meeting.

Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, confirmed it can successfully identify the “double mutant” variant of COVID-19 with its Lucira molecular test kit.